Pressmeddelande

  • Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved

    GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that…

    by
  • Invitation to a conference call and webcast in connection with Isofol receiving recommendation to complete the global Phase III AGENT study for market registration as planned with 440 patients

    GOTHENBURG, Sweden, March 22, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announced on…

    by
  • Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients

    GOTHENBURG, Sweden, March 19, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…

    by
  • Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study

    GOTHENBURG, Sweden, January 15, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…

    by
  • Isofol reaches 440 patients in global Phase III AGENT study

    GOTHENBURG, Sweden, December 9, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…

    by
  • Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

    GOTHENBURG, Sweden, November 2, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) is pleased…

    by
  • 55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study

    GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today provided an…

    by
  • Strengthened patent protection for arfolitixorin in Japan

    GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has announced today…

    by
  • Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia

    GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) has today…

    by
  • Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan

    GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) today announced…

    by